SCHEMBL825457

SCHEMBL825457

COC(=O)N1CCC(CO)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.49
ALOX5 P09917 1/20 0.44
EPHX1 P07099 1/20 0.42
EPHX2 P34913 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
THRB P10828 1/20 0.41
ATM Q13315 1/20 0.41
GAA P10253 1/20 0.41
CHRNB2 P17787 2/20 0.40
CHRNA4 P43681 2/20 0.40
CYP2D6 P10635 1/20 0.40
CHRNB4 P30926 1/20 0.40
CHRNA3 P32297 1/20 0.40
BRDT Q58F21 1/20 0.40
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
LIPE Q05469 1/20 0.38
KDM4E B2RXH2 1/20 0.38
PKM P14618 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13451380 0.85 BRD4 (0.47) BRD4EPHX1L3MBTL1THRBATM
SCHEMBL8286682 0.84 BRD4 (0.49) BRD4EPHX1EPHX2L3MBTL1THRB
SCHEMBL2464935 0.83 L3MBTL1 (0.42) BRD4ALOX5EPHX2L3MBTL1THRB
SCHEMBL14827431 0.82 BRD4 (0.51) BRD4EPHX1L3MBTL1THRBATM
SCHEMBL771084 0.82 BRD4 (0.48) BRD4EPHX1L3MBTL1THRBATM
SCHEMBL1267275 0.82 GAA (0.61) BRD4L3MBTL1THRBATMGAA
SCHEMBL25613273 0.81 BRD4 (0.47) BRD4EPHX1L3MBTL1THRBATM
SCHEMBL13451670 0.81 BRD4 (0.50) BRD4EPHX1L3MBTL1THRBATM
Hydrochloric Acid SCHEMBL28522243 0.81 BRD4 (0.50) BRD4EPHX1L3MBTL1THRBATM
SCHEMBL13498638 0.81 BRD4 (0.47) BRD4EPHX1L3MBTL1THRBATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274957-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-09-01 US disclosed
US-11254655-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2022-02-22 US disclosed
US-20200283408-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-09-10 US disclosed
US-10696656-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-06-30 US disclosed
US-10696656-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2020-06-30 US disclosed
US-20190152951-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-05-23 US disclosed
US-20190152951-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-05-23 US disclosed
US-10233172-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-03-19 US disclosed
US-10233172-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2019-03-19 US disclosed
US-20180237420-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-08-23 US disclosed
US-7256294-B2 Crystalline form of a benzimidazole-carboxamide medicinal compound THERAVANCE, INC. (US) 2007-08-14 US disclosed
US-7256294-B2 Crystalline form of a benzimidazole-carboxamide medicinal compound THERAVANCE, INC. (US) 2007-08-14 US disclosed
US-7205434-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives having a substitute on the bridgehead position; nonpeptidic compounds to treat or prevent Alzheimer's Disease by modulating the processing of amyloid precursor proteins by the putative gamma-secretas to arrest the production of beta-amyloid MERCK SHARP & DOHME LTD. (GB) 2007-04-17 US disclosed
US-7205434-B2 Sulphonamido-substituted bridged bicycloalkyl derivatives having a substitute on the bridgehead position; nonpeptidic compounds to treat or prevent Alzheimer's Disease by modulating the processing of amyloid precursor proteins by the putative gamma-secretas to arrest the production of beta-amyloid MERCK SHARP & DOHME LTD. (GB) 2007-04-17 US disclosed
US-20060270854-A1 Crystalline form of a benzimidazole-carboxamide medicinal compound THERAVANCE, INC. 2006-11-30 US disclosed
US-20060270854-A1 Crystalline form of a benzimidazole-carboxamide medicinal compound THERAVANCE, INC. 2006-11-30 US disclosed
US-20060270854-A1 Crystalline form of a benzimidazole-carboxamide medicinal compound THERAVANCE, INC. 2006-11-30 US disclosed
WO-2006127815-A2 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE, INC. (US) 2006-11-30 WO disclosed
WO-2006127815-A2 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE, INC. (US) 2006-11-30 WO disclosed
US-20060270652-A1 Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists THERAVANCE, INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233172-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-20180237420-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-20200283408-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-11254655-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-10696656-B2 Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-20220274957-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-20060270652-A1 Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists HTR4, HTR1A, HTR5A BRD4 110/4885ALOX5 818/4885EPHX1 1626/4885
US-20190152951-A1 BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR1A, HTR5A BRD4 115/4885ALOX5 944/4885EPHX1 1521/4885
US-20060270854-A1 Crystalline form of a benzimidazole-carboxamide medicinal compound HTR4, HTR5A, HTR1A BRD4 178/4885ALOX5 538/4885EPHX1 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.